Peripheral Blood-based NRN1 and TNFAIP3 Gene Expression as Minimally Invasive Biomarkers for Gastric Cancer.

IF 1.8 4区医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL

In vivo Pub Date : 2025-09-01 DOI:10.21873/invivo.14065

Daniel Soares Queiroz, Yeda Beatriz Louredo Santos, Leonardo Caires Santos, Elizabeth Suchi Chen, Carolina Oliveira Gigek, Laercio Gomes Lourenço, Carlos Haruo Arasaki, Ricardo Artigiani, Nora Manoukian Forones, Marilia Arruda Cardoso Smith, Fernanda Wisnieski

{"title":"Peripheral Blood-based NRN1 and TNFAIP3 Gene Expression as Minimally Invasive Biomarkers for Gastric Cancer.","authors":"Daniel Soares Queiroz, Yeda Beatriz Louredo Santos, Leonardo Caires Santos, Elizabeth Suchi Chen, Carolina Oliveira Gigek, Laercio Gomes Lourenço, Carlos Haruo Arasaki, Ricardo Artigiani, Nora Manoukian Forones, Marilia Arruda Cardoso Smith, Fernanda Wisnieski","doi":"10.21873/invivo.14065","DOIUrl":null,"url":null,"abstract":"Background/aim: Gastric cancer (GC) remains one of the most common and fatal cancer types worldwide. Herein, we explored neuritin 1 (NRN1) and tumor necrosis factor alpha-induced protein 3 (TNFAIP3) as minimally invasive biomarkers of GC.Materials and methods: The NRN1 and TNFAIP3 mRNA levels in the peripheral blood samples of 42 patients with GC were compared with 12 individuals with no cancer diagnosis, and monitored after gastrectomy.Results: NRN1 expression was elevated in patients compared with controls (p<0.01), and was able to discriminate between these groups (area under the curve=0.72, p=0.02). After resection of the primary tumor, NRN1 expression decreased (p<0.01), reaching levels observed in controls. TNFAIP3 expression showed no difference between patients and controls, nor postoperatively.Conclusion: Peripheral blood-based NRN1 expression can be used as a minimally invasive biomarker for GC detection and postoperative monitoring.","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 5","pages":"2646-2658"},"PeriodicalIF":1.8000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12396042/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"In vivo","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21873/invivo.14065","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background/aim: Gastric cancer (GC) remains one of the most common and fatal cancer types worldwide. Herein, we explored neuritin 1 (NRN1) and tumor necrosis factor alpha-induced protein 3 (TNFAIP3) as minimally invasive biomarkers of GC.

Materials and methods: The NRN1 and TNFAIP3 mRNA levels in the peripheral blood samples of 42 patients with GC were compared with 12 individuals with no cancer diagnosis, and monitored after gastrectomy.

Results: NRN1 expression was elevated in patients compared with controls (p<0.01), and was able to discriminate between these groups (area under the curve=0.72, p=0.02). After resection of the primary tumor, NRN1 expression decreased (p<0.01), reaching levels observed in controls. TNFAIP3 expression showed no difference between patients and controls, nor postoperatively.

Conclusion: Peripheral blood-based NRN1 expression can be used as a minimally invasive biomarker for GC detection and postoperative monitoring.

Abstract Image

查看原文本刊更多论文

外周血NRN1和TNFAIP3基因表达作为胃癌的微创生物标志物

背景/目的：胃癌（GC）仍然是世界上最常见和最致命的癌症类型之一。在此，我们探索神经素1 （NRN1）和肿瘤坏死因子α诱导蛋白3 （TNFAIP3）作为胃癌的微创生物标志物。材料与方法：将42例胃癌患者与12例未确诊胃癌患者外周血NRN1和TNFAIP3 mRNA水平进行比较，并在胃切除术后进行监测。结果：与对照组相比，患者NRN1表达升高（pp=0.02）。原发肿瘤切除后，NRN1表达降低（pTNFAIP3表达在患者和对照组之间无差异，术后亦无差异）。结论：外周血NRN1表达可作为胃癌检测和术后监测的微创生物标志物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

In vivo 医学-医学：研究与实验

CiteScore

4.20

自引率

4.30%

发文量

330

审稿时长

3-8 weeks

期刊介绍： IN VIVO is an international peer-reviewed journal designed to bring together original high quality works and reviews on experimental and clinical biomedical research within the frames of physiology, pathology and disease management. The topics of IN VIVO include: 1. Experimental development and application of new diagnostic and therapeutic procedures; 2. Pharmacological and toxicological evaluation of new drugs, drug combinations and drug delivery systems; 3. Clinical trials; 4. Development and characterization of models of biomedical research; 5. Cancer diagnosis and treatment; 6. Immunotherapy and vaccines; 7. Radiotherapy, Imaging; 8. Tissue engineering, Regenerative medicine; 9. Carcinogenesis.